Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 19;154(8):509-15.
doi: 10.7326/0003-4819-154-8-201104190-00001.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

HIV-CAUSAL Collaboration  1 ; Lauren E Cain, Roger Logan, James M Robins, Jonathan A C Sterne, Caroline Sabin, Loveleen Bansi, Amy Justice, Joseph Goulet, Ard van Sighem, Frank de Wolf, Heiner C Bucher, Viktor von Wyl, Anna Esteve, Jordi Casabona, Julia del Amo, Santiago Moreno, Remonie Seng, Laurence Meyer, Santiago Perez-Hoyos, Roberto Muga, Sara Lodi, Emilie Lanoy, Dominique Costagliola, Miguel A Hernan
Collaborators, Affiliations

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

HIV-CAUSAL Collaboration et al. Ann Intern Med. .

Abstract

Background: Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.

Objective: To identify the optimal CD4 cell count at which cART should be initiated.

Design: Prospective observational data from the HIV-CAUSAL Collaboration and dynamic marginal structural models were used to compare cART initiation strategies for CD4 thresholds between 0.200 and 0.500 × 10(9) cells/L.

Setting: HIV clinics in Europe and the Veterans Health Administration system in the United States.

Patients: 20, 971 HIV-infected, therapy-naive persons with baseline CD4 cell counts at or above 0.500 × 10(9) cells/L and no previous AIDS-defining illnesses, of whom 8392 had a CD4 cell count that decreased into the range of 0.200 to 0.499 × 10(9) cells/L and were included in the analysis.

Measurements: Hazard ratios and survival proportions for all-cause mortality and a combined end point of AIDS-defining illness or death.

Results: Compared with initiating cART at the CD4 cell count threshold of 0.500 × 10(9) cells/L, the mortality hazard ratio was 1.01 (95% CI, 0.84 to 1.22) for the 0.350 threshold and 1.20 (CI, 0.97 to 1.48) for the 0.200 threshold. The corresponding hazard ratios were 1.38 (CI, 1.23 to 1.56) and 1.90 (CI, 1.67 to 2.15), respectively, for the combined end point of AIDS-defining illness or death.

Limitations: CD4 cell count at cART initiation was not randomized. Residual confounding may exist.

Conclusion: Initiation of cART at a threshold CD4 count of 0.500 × 10(9) cells/L increases AIDS-free survival. However, mortality did not vary substantially with the use of CD4 thresholds between 0.300 and 0.500 × 10(9) cells/L.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-2963.

Figures

Appendix Figure
Appendix Figure
Follow-up for 6 hypothetical persons whose data are consistent with multiple cART initiation strategies for CD4 cell count thresholds of 0.500 and 0.350 × 109 cells/L.
Figure
Figure
Survival (top) and AIDS-free survival (bottom) for combined antiretroviral therapy initiation at CD4 cell count thresholds ranging from 0.200 to 0.500 × 109 cells/L.
See this image and copyright information in PMC

Comment in

References

    1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725–33. - PubMed
    1. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351:543–9. - PubMed
    1. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;336:378–84. - PubMed
    1. Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158:687–94. - PubMed
    1. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203. - PMC - PubMed

Publication types

MeSH terms

Substances